Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data of whole genome and circRNA from new diagnostic AML patients (with or without EMI) and healthy volunteers

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE116618 | GEO | 2018/07/04

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data of circRNA from new diagnostic AML patients (with or without EMI) and healthy volunteers

Project description:CircRNA microarray was conducted to further explore the underlying circRNA expression alterations in extramedullary infiltration (EMI) of AML. 4 matched samples from EMI, non-EMI AML patients and healthy volunteers were selected. Mononuclear cells from 12 bone marrow samples were separated according to protocols. RNA was then extracted and hybridization for further microarray analysis.

2018-07-04 | GSE116617 | GEO

Expression data of whole genome from new diagnostic AML patients (with or without EMI) and healthy volunteers

Project description:Whole Genome microarray was conducted to further explore the underlying gene expression alterations in extramedullary infiltration (EMI) of AML. 4 matched samples from EMI, non-EMI AML patients and healthy volunteers were selected. Mononuclear cells from 12 bone marrow samples were separated according to protocols. RNA was then extracted and hybridization for further microarray analysis.

2018-07-04 | GSE116616 | GEO

Expression data of circRNA from new diagnostic AML patients (with or without EMI) and healthy volunteers

Project description:Expression data of circRNA from new diagnostic AML patients (with or without EMI) and healthy volunteers

| PRJNA479516 | ENA

Expression data of whole genome and circRNA from new diagnostic AML patients (with or without EMI) and healthy volunteers

Project description:Expression data of whole genome and circRNA from new diagnostic AML patients (with or without EMI) and healthy volunteers

| PRJNA479514 | ENA

Expression data of whole genome from new diagnostic AML patients (with or without EMI) and healthy volunteers

Project description:Expression data of whole genome from new diagnostic AML patients (with or without EMI) and healthy volunteers

| PRJNA479511 | ENA

PBMCs from healthy volunteers or septic patients

Project description:This study aimed to analyze and compare the test transcripts of peripheral blood mononuclear cells (PBMCs) isolated from 4 healthy donors and 4 septic patients' whole blood.

2024-08-15 | GSE241238 | GEO

Whole blood transcriptional profiling of healthy volunteers and patients with active tuberculosis

Project description:Whole blood transcriptional profiling of healthy volunteers and patients with active tuberculosis

2016-02-09 | E-MTAB-3260 | biostudies-arrayexpress

Transimmunom whole blood RNA-seq data from type 1 diabetic patients and healthy volunteers

Project description:Patients affected by type 1 diabetes are recruited in the departments of Diabetology and Healthy Volunteers (HV) are selected based on internal records in the same hospital. Total RNA from whole blood has been extracted following a two-step procedure. First, RNA from blood collected on PAX-Gene tubes has been extracted using Maxwell 16 LEV simplyRNA blood kit (Promega) following manufacturer recommendations and second b-globin, dominant RNA from red blood cells, has been removed using the GLOBINclear kit (Ambion) on extracted RNA. RNA sequencing has been performed from using the TruSeq Stranded mRNA preparation kit (Illumina) on 500 ng b-globin depleted RNA with a RNA Integrity Number > 8 (measured on Bioanalyzer following manufacturer recommendations), and then sequenced following a pair-end 2x75 bp protocol on NextSeq 500 or HiSeq 4000 (Illumina) at LIGAN Equipex (Lille, France).

2020-06-01 | GSE123658 | GEO

Expression data from healthy volunteers and IBS patients

Project description:Micro-inflammation and gut dysfunction are features of diarrhea-irritable bowel syndrome (d-IBS) patients, although the underlying interacting molecular mechanisms remain mostly unknown. Therefore, we aimed to identify critical networks and signaling pathways active in chronic diarrhea-associated inflammation. Keywords: Comparison of gene expression

2009-02-14 | GSE14841 | GEO

Platelet Function: Meloxicam Intravenous in Whole Blood Samples From Healthy Volunteers.

Project description:Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective treatments for pain but may induce bleeding events due to platelet dysfunction associated with inhibition of cyclooxygenase (COX)-1 impairing thromboxane production. An intravenous nanocrystal formulation of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug, is under development for the treatment of moderate to severe pain. This single-center ex vivo study evaluated the effect of meloxicam intravenous and ketorolac on platelet function in whole blood samples from healthy volunteers. Each whole blood sample was aliquoted to allow analysis using a platelet function analyzer under negative control (untreated), positive control (2 therapeutic ketorolac concentrations), and meloxicam intravenous (1 therapeutic, 3 supratherapeutic concentrations) using both collagen with epinephrine and collagen with adenosine diphosphate reagent cartridges. The platelet function analyzer determines closure time by simulating platelet adhesion and aggregation following vascular injury. The final analysis set included data from 8 subjects. The collagen with adenosine diphosphate analysis (sensitive to thrombocytopathies) showed no significant differences in closure time for meloxicam- or ketorolac-treated samples and untreated control. The collagen with epinephrine analysis (sensitive to aspirin-induced platelet abnormalities) produced no significant difference in closure time between any meloxicam concentration and untreated control. Ketorolac was associated with significantly longer closure times vs untreated control at both the 2.5- and 5-µg/mL concentrations (P = .003 and .0257, respectively) and vs meloxicam at several concentrations. Similar results were observed when all analyzed samples were included. Meloxicam intravenous had no significant effect on closure times at therapeutic or supratherapeutic concentrations in this ex vivo study.

| S-EPMC7587000 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data